Aprecia Pharmaceuticals and FabRx– Major Players in 3D Printed Drugs Market
3D Printed Drugs are medications, which are designed by 3D printing technique to customize for the individuals in a safer and effective way. These drugs have unitary porous structures that readily disperse in the mouth, because of which these high-dose medicines need not to be swallowed intact. The main idea behind 3D printing drugs is to design and develop medicines that are suited to an individual’s needs.
Market leaders operating in the market have undertaken various organic growth strategies in the 3D printed drugs market. The 3D printed drugs market majorly consists of the players such APRECIA PHARMACEUTICALS, LLC, FabRx LTD, Cycle Pharmaceuticals, GLAXOSMITHKLINE PLC., ASTRAZENECA, Tvasta, and Merck KGGA amongst others. Several organic approaches, such as product launches, and expansion/relocation in the 3D printed drugs market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Below is the list of the growth strategies done by the players operating in the 3D printed drugs market:
|
Year |
News |
|
Feb-2020 |
Merck entered into strategic collaboration with AMCM with an aim to develop 3D printed tablets. Based on this collaboration, AMCM has agreed to provide its customized additive manufacturing solutions for the manufacturing of 3D printed tablets. |
|
Jan-2020 |
AstraZeneca entered in research collaboration with Quotient Sciences Ltd and Added Scientific Ltd. with an aim to assess the clinical applications of 3D printing for solid dosage forms. Additionally, the pharmaceutical companies also received MRC Confidence in Concepts grant, which will definitely accelerate the research and development activities. |
|
Apr-2020 |
FabRx Ltd. has released the first pharmaceutical 3D printer M3DIMAKER for the manufacture of personalised medicines. The novel system was first introduced at the ILMAC Exhibition in Basel (Switzerland) on the September 2019. |
|
Aug-2015 |
Aprecia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM levetiracetam for oral use. SPRITAM utilizes Aprecia’s proprietary ZipDose Technology platform. |
